Related Experiment Video

Updated: Jul 20, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells

Axel Priebsch1, Franziska Rompe, Holger Tönnies

  • 1Charité Campus Mitte, Institute of Pathology, D-10117 Berlin, Germany.

Oligonucleotides
|September 19, 2006
PubMed

Insights

Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) effectively silenced ABCG2, overcoming multidrug resistance in cancer cells. This RNA interference-based gene therapy reversed drug resistance and increased drug accumulation in treated cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • The ABCG2 transporter is implicated in atypical MDR phenotypes of cancer cells.

Purpose of the Study:

  • To investigate the potential of RNA interference (RNAi) to overcome ABCG2-dependent MDR.
  • To evaluate the efficacy of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) targeting ABCG2.

Main Methods:

  • Designed and utilized two anti-ABCG2 siRNAs for transient gene silencing.
  • Constructed shRNA expression vectors for stable inhibition of ABCG2.
  • Assessed gene and protein expression, cellular drug accumulation, and drug-resistant phenotype in EPG85-257RNOV gastric carcinoma cells.

Main Results:

  • Both siRNAs demonstrated biological activity in silencing ABCG2.
  • shRNA treatment led to complete inhibition of ABCG2 mRNA and protein expression.
  • Anti-ABCG2 shRNA-treated cells showed restored cellular drug accumulation and complete reversal of the MDR phenotype.

Conclusions:

  • siRNA- and shRNA-mediated RNAi is a promising strategy for preventing and reversing ABCG2-dependent atypical MDR.
  • RNAi-based gene therapy holds potential for enhancing the efficacy of chemotherapeutic treatments.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...